Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors

Added 243 days ago (19.01.2021)
Authors: Rahma, O. E., Reuss, J. E., Giobbie-Hurder, A., Shoja E Razavi, G., Abu-Shawer, O., Mehra, P., Gupta, S., Simon, R., Khleif, S. N.
Read article